by Claire | Nov 21, 2022 | Uncategorized
Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer’s Disease —Diadem to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference— Milan, Italy, November 21, 2022 – Diadem...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM NAMES CLINICAL DIAGNOSTICS INDUSTRY VETERAN PAUL KINNON AS CEO —Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease— —Accessible Early Diagnosis Will Transform...
by Claire | Oct 23, 2022 | Uncategorized
DEVELOPMENT OF BLOOD-BASED ALZHEIMER’S PROGNOSTIC PROPELS DIADEM TO FINALIST STATUS FOR BOTH THE GAETANO MARZOTTO COMPANY PRIZE AND 2030 SOCIAL IMPACT SPECIAL PRIZE —Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM NAMES DR. TAMAS BARTFAI CHAIR OF ITS MEDICAL ADVISORY BOARD —Dr. Bartfai Brings Broad Academic and Pharma Industry Experience to Medical Advisory Board Comprised of Distinguished Alzheimer’s Disease Researchers and Opinion Leaders — Milan, ITALY – December 1,...